This category addresses the science behind antibodies that target two distinct epitopes. Topics include design considerations, production methods, and therapeutic applications.
Bispecifics vs. monoclonals: what’s the difference? Biointron outlines structural contrasts and therapeutic applications of each format.
Bispecific antibodies transform in vivo research. Biointron highlights how BsAbs expand therapeutic potential by targeting multiple pathways with precision.
Bispecific ADCs advance oncology. Biointron shows how dual-targeted antibody-drug conjugates improve precision, efficacy, and patient outcomes in cancer treatment.
Bispecific antibodies are transforming medicine. Biointron highlights their design, therapeutic applications, and development pathways for next-generation therapies.
Bispecific antibodies target two antigens at once. Biointron explores their formats, advantages, and therapeutic potential across cancer, immunology, and emerging indications.
Biointron delivers advanced bispecific antibody production with over 260 proven formats, offering rapid expression, scalable solutions, and trusted CRO expertise for therapeutic development.
Antibody engineering drives therapeutic innovation. Biointron advances bispecific design, Fc optimization, and humanization to enhance potency, reduce risks, and accelerate development.
You can also contact us on the Scientist and Science Exchange marketplaces.
Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.
